Rohan Parikh

Triangle — United States

Medicine · Health Sciences

14h-index692citations121works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(16), Neuroendocrine Tumor Research Advances(9), Healthcare Policy and Management(8), Acute Myeloid Leukemia Research(7), Lung Cancer Treatments and Mutations(7)

Publications121 total

Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US
Blood·2025Open Access
REAL-WORLD CLINICAL OUTCOMES OF LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB FOR THE TREATMENT OF PATIENTS WITH NON-MSI-H/PMMR RECURRENT OR ADVANCED ENDOMETRIAL CANCER IN THE UNITED STATES
International Journal of Gynecological Cancer·2025Open Access
S912 Dupilumab Treatment Patterns for Eosinophilic Esophagitis in the United States: A Real-World Study
The American Journal of Gastroenterology·2025
Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2− advanced breast cancer in Europe
Breast Cancer Research and Treatment·2025· 1 citedOpen Access
Disease burden, diagnosis pathways and treatment patterns in patients with eosinophilic esophagitis: a real-world study
European Journal of Gastroenterology & Hepatology·2025Open Access
Real-world (RW) outcomes of patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) receiving first-line (1L) luspatercept (LUSPA) or 1L erythropoiesis-stimulating agents (ESA) in the US.
Journal of Clinical Oncology·2025
211P Risk of recurrence (ROR) among patients (pts) with HR+/HER2− early breast cancer (EBC) involving 1-3 axillary lymph nodes (N1): A real-world evaluation
ESMO Open·2025Open Access
Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia
Cancer·2025· 1 cited
Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
ClinicoEconomics and Outcomes Research·2025· 2 citedOpen Access
Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib
Future Oncology·2025· 3 citedOpen Access
Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe
Future Oncology·2024· 2 citedOpen Access
Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US.
Journal of Clinical Oncology·2024
Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States
Frontiers in Oncology·2024Open Access
Treatment Patterns and Persistent Disease Activity in Patients With Eosinophilic Esophagitis: A Retrospective Cohort Study
Gastro Hep Advances·2024· 3 citedOpen Access
Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib
Blood·2023· 1 citedOpen Access
Using the Maryland Park Equity Tool to Correlate Park Space with Children's Health in Baltimore, Maryland
Environmental Justice·2023· 2 cited
CO162 A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients with Metastatic Renal Cell Carcinoma in Latin America
Value in Health·2023Open Access
213P Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe
ESMO Open·2023· 1 citedOpen Access
222P Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER)
ESMO Open·2023Open Access
Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer
Cardio-Oncology·2023· 19 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Xianglin L. Du(10), David R. Lairson(10), Elizabeth Esterberg(8), James A. Kaye(6), Lee Stern(5), Samantha K. Kurosky(4), Luisa Franzini(4), Janice N. Cormier(4), Sean D. Candrilli(3), Chapin White(3), Suthira Taychakhoonavudh(3), Keith L. Davis(3), Sarju Ganatra(3), Sourbha S. Dani(3), Wenyaw Chan(3), Maruit Chulikavit(3), Zhimei Liu(3), Jan Stålhammar(2), Ragnar Linder(2), Rinat Ariely(2)